An interventional study of Endoscopic Radial Compression Gastroplasty and Optimized Lifestyle Intervention (OLI) in Overweight and/or Obesity, Metabolic Syndrome and Nonalcoholic Fatty Liver Disease, sponsored by Liu Yan. Recruiting at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Liu Yan · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Metabolic Syndrome with a site in China — 35 open to participants now, 39 under way, 1 of them phase 3. Metabolic Syndrome · China.
Among the 89 studies in Metabolic Syndrome with a site in China, this one is the 11th largest by planned enrollment of the 50 interventional ones that give a count, is one of 9 that started in 2026, is one of 39 with no phase, reaches primary completion later than 25 of the 38 other live ones, and was the 74th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →35 of the 89 studies in Metabolic Syndrome with a site in China are open now. Recruiting first, the newest first:
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18–65
Zhujiang Hospital · Sites in China
Ages 18–60
Hudson Biotech · Sites in China
Ages 18–65
Meihua Ji · Sites in China
Ages 18–75
Shanghai Changzheng Hospital · Sites in China
Ages 18+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 6 · Phase 4 4
First in 2000; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 216 is above the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 143 across the 50 interventional studies, 1,249 across the 39 observational. Of the 39 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 89 have an industry lead sponsor. The 10 most frequent:
Liu Yan is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Liu Yan has 1 study filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
12 of the studies in Metabolic Syndrome with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05105321Tang YidaCardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP) | 2026-12 |
| NCT07096102Meihua JiEfficacy of a Health Empowerment Theory Based Health Information Literacy Promotion Intervention in Individuals With Metabolic Syndrome | 2026-12-30 |
| NCT07327684Peking Union Medical College HospitalPhotoacoustic/Ultrasound Imaging of Brown Adipose Tissue Activity | 2026-12-31 |
| NCT07822763First Affiliated Hospital of Chongqing Medical UniversityPreoperative Oral Carbohydrate Loading and Gastrointestinal Recovery After Bariatric Surgery in Metabolic Syndrome | 2027-01 |
| NCT07505745Hudson BiotechMOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity | 2027-02-14 |
Add all 12 to your calendar (.ics) → With an account.
Among the 89 studies in Metabolic Syndrome with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, sham-controlled trial evaluates the efficacy and safety of ERCG plus optimized lifestyle intervention compared with sham procedure plus optimized lifestyle intervention in Chinese adults with overweight accompanied by at least one metabolic comorbidity or with mild-to-moderate obesity. The co-primary outcomes are percentage total weight loss (%TWL) at 12 weeks and the clinical response rate at 12 weeks, defined as the proportion of participants achieving %TWL ≥5%. Secondary outcomes include weight-related, metabolic, hepatic steatosis-related, imaging, symptom, quality-of-life, and safety outcomes.
The prevalence of obesity and overweight continues to increase worldwide, and Chinese populations are particularly vulnerable due to lower thresholds for metabolic risk compared with Western populations. Individuals with overweight or mild-to-moderate obesity (BMI 24.0-37.4 kg/m²) often fail conservative measures but are ineligible or unwilling to undergo bariatric surgery because of its invasiveness, risk, and costs. This creates an unmet need for minimally invasive, effective, and scalable interventions.
Endoscopic bariatric and metabolic therapies (EBMTs) have emerged as alternatives, but many existing procedures involve technically complex endoscopic suturing, high costs, or device-related risks. Investigators developed ERCG, a novel endoscopic procedure that reduces gastric volume by apposing the gastric walls using a newly designed clip-and-loop system. Preliminary studies demonstrated that ERCG can induce rapid weight loss, with mean percent total body weight loss (TBWL) of approximately 12% at 3 months, while maintaining a favorable safety profile.
This randomized controlled trial aims to evaluate the efficacy and safety of ERCG compared with an optimized lifestyle intervention (OLI) in Chinese adults with overweight and mild-to-moderate obesity who have failed conservative weight reduction efforts. Eligible participants will be randomized in a 1:1 ratio to ERCG plus optimized lifestyle intervention or sham procedure plus optimized lifestyle intervention. Participants in both groups will undergo the assigned procedure under the same anesthesia strategy and procedural setting. The sham procedure will simulate the duration and peri-procedural experience of ERCG without clip or endoloop placement, gastric wall traction, or gastric volume reduction. Both groups will receive the same optimized lifestyle intervention and follow-up schedule. Follow-up visits are scheduled at 1 month, 2 month, 3 month and 6 month after enrollment.
The primary endpoint is percent TBWL at 3 months, assessed using standardized weight measurement protocols. Secondary endpoints include %EBWL at 3 and 6 months, changes in BMI, metabolic parameters (fasting plasma glucose, HbA1c, insulin resistance indices, lipid profile), quality of life assessed by validated questionnaires (IWQOL-Lite), and the incidence of adverse events classified according to international standards.
Randomization will be computer-generated with concealed allocation, and outcome assessors will be blinded to treatment assignment. Analyses will follow the intention-to-treat principle with appropriate methods for handling missing data.
The study is expected to generate high-quality evidence regarding the short-term and medium-term efficacy of ERCG, to clarify its safety profile, and to determine whether ERCG can serve as a safe and scalable option bridging the therapeutic gap between conservative lifestyle approaches and bariatric surgery for overweight and mildly to moderately obese Chinese populations.
The criteria were revised on the registry on Oct 26, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sutureless endoscopic gastric volume reduction using a clip-and-loop apposition system under non-intubated general anesthesia, plus standardized OLI (dietary counseling, calorie deficit, physical activity prescription, and behavioral support) with visit frequency matched to the comparator.
Procedure: Endoscopic Radial Compression Gastroplasty · Behavioral: Optimized Lifestyle Intervention (OLI)
Participants assigned to the control group will undergo a sham endoscopic procedure under the same anesthesia strategy and procedural setting as the ERCG group. The sham procedure will include routine upper gastrointestinal endoscopy and non-therapeutic maneuvers, such as insufflation, suction, and irrigation, with a total procedure-related duration of approximately 25 minutes. No endoscopic clips or endoloops will be deployed, and no gastric wall traction or gastric volume-reduction procedure will be performed. Participants will subsequently receive the same optimized lifestyle intervention and follow-up schedule as the ERCG group.
Behavioral: Optimized Lifestyle Intervention (OLI) · Procedure: Sham Endoscopic Procedure
Sutureless endoscopic gastric volume reduction using a novel clip-and-endoloop apposition system; performed under general anesthesia or deep sedation; standard perioperative care.
Structured nutrition counseling, calorie deficit plan, physical activity prescription per regional guidelines, and behavioral support; visit frequency matched to the ERCG arm.
A sham upper gastrointestinal endoscopic procedure performed under the same anesthesia strategy and procedural setting as ERCG. The procedure includes routine examination of the esophagus, stomach, and duodenum and may include non-therapeutic maneuvers such as insufflation, suction, and irrigation. No clips or endoloops are deployed, and no gastric wall traction or gastric volume-reduction procedure is performed. The total procedure-related duration is approximately 25 minutes.
Percent Total Body Weight Loss (%TBWL)
Percentage total weight loss at 12 weeks will be calculated as: %TWL = \[(baseline body weight - body weight at 12 weeks) / baseline body weight\] × 100%. Body weight will be measured under standardized conditions.
Time frame: 12 weeks after the assigned procedure
Clinical Responder Rate (CRR)
The clinical response rate is defined as the proportion of participants achieving %TWL ≥5% at 12 weeks. Percentage total weight loss will be calculated as: %TWL = \[(baseline body weight - body weight at 12 weeks) / baseline body weight\] × 100%.
Time frame: 12 weeks after the assigned procedure
Body Weight (kg)
Weight measured on a calibrated scale under standardized conditions (light clothing, no shoes, preferably morning after ≥8h fasting).
Time frame: Baseline, 3 month, 6month
Body Height (m)
Standing height measured with a wall-mounted stadiometer, no shoes, heels together, Frankfurt plane horizontal.
Time frame: Baseline
Percent Excess Body Weight Loss (%EBWL)
%EBWL is calculated as \[(Baseline weight - Follow-up weight) / (Baseline weight - Ideal weight)\] × 100. Ideal weight is defined as the weight corresponding to a BMI of 23.9 kg/m². Weight is measured using a calibrated scale under standardized fasting conditions at each visit.
Time frame: 3 and 6 months post-intervention
Change in BMI (kg/m²)
BMI will be calculated as weight (kg) divided by height squared (m²).
Time frame: 3 and 6 months post-intervention
Glycated Hemoglobin (HbA1c)
HbA1c will be measured using standard laboratory methods. Values at each visit and changes from baseline will be summarized.
Time frame: Baseline, 3 and 6 months
Adverse Events (AEs/SAEs) Related to Procedure
Number and proportion of participants with device-/procedure-related AEs/SAEs, graded by Clavien-Dindo and per FDA/ISO definitions.
Time frame: Baseline, 3 and 6 months
GERD-Q Total Score
Gastroesophageal Reflux Disease Questionnaire (GERD-Q) total score, validated 6-item instrument. Higher scores indicate more severe reflux symptoms.
Time frame: Baseline, 3, and 6 months
Postoperative Pain (VAS/NRS)
Patient-reported pain intensity using a 0-10 scale (0=no pain, 10=worst imaginable pain). Assessed at rest.
Time frame: 6 hours, 24 hours, and 7 days
Postoperative Nausea Score
Patient-reported nausea severity using a 0-10 numeric rating scale (0=no nausea, 10=worst nausea).
Time frame: 6 hours, 24 hours, and 7 days
Total Cholesterol
Total cholesterol will be measured after an overnight fast using standard laboratory methods. Values at each visit and changes from baseline will be summarized.
Time frame: Baseline, 3 and 6 months
Low-Density Lipoprotein Cholesterol (LDL-C)
LDL-C will be measured directly or calculated using standard methods. Values at each visit and changes from baseline will be summarized.
Time frame: Baseline, 3 and 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.
Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 12 months is below that.
Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Dec 2026 → Mar 2027 and completion May 2027 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Liu Yan